ARS Pharmaceuticals, Inc. Lease, Cost
ARS Pharmaceuticals, Inc. (SPRY) reported Lease, Cost of $153.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2025-11-10
- ARS Pharmaceuticals, Inc. lease, cost for the quarter ending 2025-09-30 was $153.00K, a 173.21% increase year-over-year.
- ARS Pharmaceuticals, Inc. lease, cost for the quarter ending 2025-06-30 was $159.00K, a 178.95% increase year-over-year.
- ARS Pharmaceuticals, Inc. lease, cost for the quarter ending 2025-03-31 was $60.00K, a 7.14% increase year-over-year.
- ARS Pharmaceuticals, Inc. lease, cost for the quarter ending 2024-09-30 was $56.00K.
- ARS Pharmaceuticals, Inc. lease, cost for fiscal 2021 was $1.91M, a 7.72% increase from fiscal 2020.
- ARS Pharmaceuticals, Inc. lease, cost for fiscal 2020 was $1.77M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-09-30 | $153.00K 10-Q · filed 2025-11-10 | $312.00K derived: sum of 2 quarters · filed 2025-11-10 | $372.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $159.00K 10-Q · filed 2025-08-13 | $219.00K 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $60.00K 10-Q · filed 2025-05-14 | |||
| 2024-09-30 | $56.00K 10-Q · filed 2025-11-10 | $113.00K derived: sum of 2 quarters · filed 2025-11-10 | $169.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $57.00K 10-Q · filed 2025-08-13 | $113.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $56.00K 10-Q · filed 2025-05-14 | |||
| 2022-09-30 | $453.00K 10-Q · filed 2022-11-02 | $934.00K derived: sum of 2 quarters · filed 2022-11-02 | $1.43M 10-Q · filed 2022-11-02 | $1.91M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | $481.00K 10-Q · filed 2022-08-11 | $972.00K 10-Q · filed 2022-08-11 | $1.45M derived: sum of 3 quarters · filed 2022-08-11 | $1.98M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | $491.00K 10-Q · filed 2022-05-12 | $973.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.50M derived: sum of 3 quarters · filed 2022-11-02 | $1.95M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.00M derived: sum of 2 quarters · filed 2022-11-02 | $1.46M derived: sum of 3 quarters · filed 2022-11-02 | $1.91M 10-K · filed 2022-03-31 |
| 2021-09-30 | $523.00K 10-Q · filed 2022-11-02 | $976.00K derived: sum of 2 quarters · filed 2022-11-02 | $1.43M 10-Q · filed 2022-11-02 | $1.86M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $453.00K 10-Q · filed 2022-08-11 | $906.00K 10-Q · filed 2022-08-11 | $1.34M derived: sum of 3 quarters · filed 2022-08-11 | $1.81M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $453.00K 10-Q · filed 2022-05-12 | $887.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.35M derived: sum of 3 quarters · filed 2022-05-12 | $1.79M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $434.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $900.00K derived: sum of 2 quarters · filed 2022-03-31 | $1.34M derived: sum of 3 quarters · filed 2022-03-31 | $1.77M 10-K · filed 2022-03-31 |
| 2020-09-30 | $466.00K 10-Q · filed 2021-11-10 | $907.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.34M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $441.00K 10-Q · filed 2021-08-12 | $874.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $433.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |